Literature DB >> 27541382

Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer.

Geoffrey R Oxnard1, Cloud P Paweletz2, Lynette M Sholl3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27541382     DOI： 10.1001/jamaoncol.2016.2835

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  29 in total

1.  Efficacy of vemurafenib in a heavy smoker with BRAF-mutated lung adenocarcinoma: A case report and literature review.

Authors:  Xue Liu; Xuefeng Fang; Hanguang Hu; Xianhua Fu; Ying Chen; Ying Yuan
Journal:  Mol Clin Oncol       Date:  2018-08-06

2.  Tissue Acquisition in Clinical Trials-Essential for Progress.

Authors:  S Percy Ivy; Jeffrey S Abrams
Journal:  J Natl Cancer Inst       Date:  2017-04-01       Impact factor: 13.506

3.  Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies.

Authors:  Sawsan Rashdan; David E Gerber
Journal:  Ann Transl Med       Date:  2016-12

Review 4.  Liquid Biopsy to Identify Actionable Genomic Alterations.

Authors:  Sai-Hong Ignatius Ou; Misako Nagasaka; Viola W Zhu
Journal:  Am Soc Clin Oncol Educ Book       Date:  2018-05-23

Review 5.  Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice.

Authors:  Charu Aggarwal; Christian D Rolfo; Geoffrey R Oxnard; Jhanelle E Gray; Lynette M Sholl; David R Gandara
Journal:  Nat Rev Clin Oncol       Date:  2020-09-11       Impact factor: 66.675

Review 6.  Molecular diagnostics of lung cancer in the clinic.

Authors:  Lynette Sholl
Journal:  Transl Lung Cancer Res       Date:  2017-10

Review 7.  Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer.

Authors:  Michael Lam; Jonathan M Loree; Allan Anderson Lima Pereira; Yun Shin Chun; Scott Kopetz
Journal:  Curr Treat Options Oncol       Date:  2018-02-27

8.  ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.

Authors:  Alice T Shaw; Benjamin J Solomon; Benjamin Besse; Todd M Bauer; Chia-Chi Lin; Ross A Soo; Gregory J Riely; Sai-Hong Ignatius Ou; Jill S Clancy; Sherry Li; Antonello Abbattista; Holger Thurm; Miyako Satouchi; D Ross Camidge; Steven Kao; Rita Chiari; Shirish M Gadgeel; Enriqueta Felip; Jean-François Martini
Journal:  J Clin Oncol       Date:  2019-03-20       Impact factor: 44.544

9.  Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.

Authors:  Ibiayi Dagogo-Jack; A Rose Brannon; Lorin A Ferris; Catarina D Campbell; Jessica J Lin; Katherine R Schultz; Jennifer Ackil; Sara Stevens; Leila Dardaei; Satoshi Yoda; Harper Hubbeling; Subba R Digumarthy; Markus Riester; Aaron N Hata; Lecia V Sequist; Inga T Lennes; A John Iafrate; Rebecca S Heist; Christopher G Azzoli; Anna F Farago; Jeffrey A Engelman; Jochen K Lennerz; Cyril H Benes; Rebecca J Leary; Alice T Shaw; Justin F Gainor
Journal:  JCO Precis Oncol       Date:  2018-01-23

Review 10.  Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers.

Authors:  Manuel Caitano Maia; Meghan Salgia; Sumanta K Pal
Journal:  Nat Rev Urol       Date:  2020-03-17       Impact factor: 14.432
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.